Filtered By:
Source: Clinical Cardiology

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 111 results found since Jan 2013.

Advances in Stroke Prevention in Atrial Fibrillation: Enhanced Risk Stratification Combined With the Newer Oral Anticoagulants
Abstract Patients with atrial fibrillation (AF) have an increased stroke risk compared with those in sinus rhythm, although the absolute risk for individual patients is modulated by the presence of various additional risk factors. Patient selection for oral anticoagulation for stroke prevention is based on risks of stroke and bleeding. Although CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack) is the most widely used scheme for evaluating stroke risk in patients with AF, several other stroke risk factors are not included; therefore, many patients' strok...
Source: Clinical Cardiology - April 1, 2013 Category: Cardiology Authors: Freek W. A. Verheugt Tags: Review Source Type: research

Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation
ConclusionsHigh MPV and AT‐III deficiency were predictive markers for stroke or LA thrombus. Their predictive power for stroke was independent of antiplatelet treatment, anticoagulation therapy, and a high CHA2DS2‐VASc score in patients with AF.
Source: Clinical Cardiology - August 1, 2017 Category: Cardiology Authors: Seo ‐Won Choi, Bo‐Bae Kim, Dong‐Hyun Choi, Geon Park, Byung Chul Shin, Heesang Song, DongHun Kim, Dong‐Min Kim Tags: CLINICAL INVESTIGATIONS Source Type: research

Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk‐Score Acronyms (CHADS2, CHA2DS2‐VASc, R2CHADS2, HAS‐BLED, ATRIA, and More)
ABSTRACT Stroke prevention is central to the management of patients with atrial fibrillation (AF). As effective stroke prophylaxis essentially requires oral anticoagulants, an understanding of the risks and benefits of oral anticoagulant therapy is needed. Although AF increases stroke risk 5‐fold, this risk is not homogeneous. Many stroke risk factors also confer an increased risk of bleeding. Various stroke and bleeding risk‐stratification schemes have been developed to help inform clinical decision‐making. These scores were derived and validated in different study cohorts, ranging from highly selected clinical‐tr...
Source: Clinical Cardiology - August 1, 2014 Category: Cardiology Authors: Mikhail S. Dzeshka, Deirdre A. Lane, Gregory Y. H. Lip Tags: Reviews Source Type: research

Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project
ConclusionsIn Chinese AF patients, the benefits of warfarin therapy for stroke prevention and ICH reduction depend on TTR. Of the treatments compared, dabigatran, as well as rivaroxaban 20 mg daily, was associated with lowest ischemic stroke and ICH rates.
Source: Clinical Cardiology - September 30, 2016 Category: Cardiology Authors: Wen ‐Hua Li, Duo Huang, Chern‐En Chiang, Chu‐Pak Lau, Hung‐Fat Tse, Esther W. Chan, Ian C.K. Wong, Gregory Y. H. Lip, Pak‐Hei Chan, Chung‐Wah Siu Tags: Clinical Investigations Source Type: research

Stroke and Systemic Embolism After Successful Ablation of Typical Atrial Flutter
ConclusionsPatients with AFL who undergo successful ablation are by no means free from embolic complications during long‐term follow‐up, mainly due to a high rate of AF development. Given the difficulties in detecting AF and the uncertainty about the temporal relation of AF and stroke, oral anticoagulation may need to be continued in those patients with underlying stroke risk factors.
Source: Clinical Cardiology - March 29, 2016 Category: Cardiology Authors: Víctor Expósito, Felipe Rodríguez‐Entem, Susana González‐Enríquez, Gabriela Veiga, Iván Olavarri, Juan J. Olalla Tags: Clinical Investigations Source Type: research

Cost‐Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation—A Real Patient Data Analysis in a Hong Kong Teaching Hospital
ConclusionsThe study favored dabigatran for stroke prophylaxis in patients with nonvalvular AF in Hong Kong under the current hospital's perspective and provided a reference for further comparisons under patient and subsidization perspectives.
Source: Clinical Cardiology - March 14, 2013 Category: Cardiology Authors: Andy M. Chang, Jason C. S. Ho, Bryan P. Yan, Cheuk Man Yu, Yat Yin Lam, Vivian W. Y. Lee Tags: Clinical Investigation Source Type: research

Stroke After Transcatheter Aortic Valve Replacement: Incidence, Risk Factors, Prognosis, and Preventive Strategies
Abstract The first transcatheter aortisc valve replacement (TAVR) was performed in 2002, and has been proven beneficial in inoperable and high‐risk patients for open heart surgery. Stroke occurrence after TAVR, both periprocedure and at follow‐up, has not been well described. We sought to review incidence, pathophysiology, predictors, prognosis, and current preventive strategies of cerebrovascular accidents (CVAs) after TAVR. Studies were selected from a Medline search if they contained clinical outcomes data after TAVR. Acute and subacute CVAs after TAVR have been reported in 3% to 6% of patients. Approximately 45% of...
Source: Clinical Cardiology - October 1, 2014 Category: Cardiology Authors: Ioannis Mastoris, Mikkel M. Schoos, George D. Dangas, Roxana Mehran Tags: Reviews Source Type: research

Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry
ConclusionsIn this study, residual ischemic risk after MI accrued progressively up to 4 years of follow‐up, emphasizing the value of intensive secondary prevention strategies to minimize residual risk.
Source: Clinical Cardiology - July 31, 2016 Category: Cardiology Authors: J érémie Abtan, Deepak L. Bhatt, Yedid Elbez, Emmanuel Sorbets, Kim Eagle, Yasuo Ikeda, David Wu, Mary E. Hanson, Hakima Hannachi, Puneet K. Singhal, Philippe Gabriel Steg, Gregory Ducrocq, Tags: Clinical Investigations Source Type: research

Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation
Atrial fibrillation (AF) is a commonly sustained atrial arrhythmia with associated morbidity and mortality. AF is associated with increased risk of thromboembolism and stroke, requiring use of anticoagulation. Anticoagulation decreases the risk of stroke but is associated with a higher risk of bleeding, necessitating discontinuation in some patients. The left atrial appendage is the likely source of thrombus in the majority of patients with AF. This has led to the development of left atrial appendage occlusion as a means to reduce stroke risk in patients who have a contraindication to long‐term anticoagulation. Multiple ...
Source: Clinical Cardiology - July 27, 2017 Category: Cardiology Authors: Rizma Jalees Bajwa, Lara Kovell, Jon R. Resar, Armin Arbab ‐Zadeh, Kaushik Mandal, Hugh Calkins, Ronald D. Berger Tags: REVIEW Source Type: research

Relation of premature atrial complexes with stroke and death: Systematic review and meta ‐analysis
Frequent premature atrial complexes (PACs) are universal in the general population; however, their clinical significance is unclear. We hypothesize that frequent PACs are associated with increased risk of stroke and death. The PubMed (from 1966 to April 2017) and Embase (from 1974 to April 2017) databases were searched for longitudinal studies that reported the relation of PACs with incidence of stroke and death with various etiologies. Study quality was evaluated, and the relative risks (RR) of unfavorable outcomes in subjects with frequent PACs vs those without were calculated. Eleven studies with overall high quality we...
Source: Clinical Cardiology - August 28, 2017 Category: Cardiology Authors: Bao ‐tao Huang, Fang‐yang Huang, Yong Peng, Yan‐biao Liao, Fei Chen, Tian‐li Xia, Xiao‐bo Pu, Mao Chen Tags: REVIEW Source Type: research

Laboratory characteristics of ischemic stroke patients with atrial fibrillation on or off therapeutic warfarin
ConclusionsAF patients who presented with IS on therapeutic warfarin had higher average serum creatinine and blood urea nitrogen, and lower glomerular filtration rates, compared with others. Impaired renal function may be a factor contributing to occurrence of IS in AF patients despite adequate anticoagulation. Larger, targeted studies are needed to confirm these findings.
Source: Clinical Cardiology - November 1, 2017 Category: Cardiology Authors: Raghav V. Aachi, Lee A. Birnbaum, Christopher H. Topel, Ali Seifi, Shaheryar Hafeez, R éza Behrouz Tags: CLINICAL INVESTIGATIONS Source Type: research

Stroke prevention strategies in North American patients with atrial fibrillation: the GLORIA ‐AF registry program
ConclusionsIn GLORIA‐AF, 20% of the population comprising males with CHA2DS2‐VASc ≥1 and females with CHA2DS2‐VASc ≥2 did not receive oral anticoagulation therapy. Patient characteristics associated with a lower likelihood of OAC prescription were use of antiplatelet drugs, paroxysmal pattern of AF, a history of falls, and prior bleeding.
Source: Clinical Cardiology - February 1, 2018 Category: Cardiology Authors: William F. McIntyre, David Conen, Brian Olshansky, Jonathan L. Halperin, Emil Hayek, Menno V. Huisman, Gregory Y.H. Lip, Shihai Lu, Jeff S. Healey Tags: CLINICAL INVESTIGATIONS Source Type: research

Benefit of Anticoagulation Therapy in Hyperthyroidism‐Related Atrial Fibrillation
ConclusionsPatients with hyperthyroidism‐related AF are at high risk of stroke (3.9% per year). Warfarin confers stroke prevention in patients with CHA2DS2‐VASc ≥1 and non–self‐limiting AF. Overall stroke risk was lower in hyperthyroid non–self‐limiting AF patients compared with nonhyperthyroid counterparts.
Source: Clinical Cardiology - July 1, 2015 Category: Cardiology Authors: Pak‐Hei Chan, Jojo Hai, Chun‐Yip Yeung, Gregory Y.H. Lip, Karen Siu‐Ling Lam, Hung‐Fat Tse, Chung‐Wah Siu Tags: Clinical Investigations Source Type: research

Novel Oral Anticoagulants in Atrial Fibrillation: A Meta‐analysis of Large, Randomized, Controlled Trials vs Warfarin
Conclusions:Novel oral anticoagulants may be superior to warfarin in patients with atrial fibrillation, reducing the composite of stroke or systemic embolism and lowering all‐cause mortality. The benefit is largely due to fewer hemorrhagic strokes.Ernesto Paolasso, MD, is a national lead investigator for a clinical trial sponsored by Daiichi‐Sankyo investigating a novel oral anticoagulant. Robert Giugliano, MD, SM, is a member of the TIMI Study Group, which has received research grant support from Johnson & Johnson and from Daiichi‐Sankyo related to clinical trials of anticoagulants. Dr. Giugliano has received ho...
Source: Clinical Cardiology - January 1, 2013 Category: Cardiology Authors: Ariel Dogliotti, Ernesto Paolasso, Robert P. Giugliano Tags: Review Source Type: research

Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial
ConclusionsPatients with CD in ROCKET AF had similar risk of stroke/SE compared with patients without CD. Additionally, there was no interaction between CD and the treatment effect of rivaroxaban or warfarin for stroke prevention or safety endpoints.
Source: Clinical Cardiology - December 1, 2017 Category: Cardiology Authors: Ajar Kochar, Anne S. Hellkamp, Yuliya Lokhnygina, W. Schuyler Jones, Richard C. Becker, Scott D. Berkowitz, G ünter Breithardt, Keith A.A. Fox, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Daniel E. Singer, Jonathan Tags: CLINICAL INVESTIGATIONS Source Type: research